Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)

Melbourne (Australia) | 22 January 2024

Telix today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA (US) from 25 – 27 January 2024. 

Dr David N. Cade, Telix Group Chief Medical Officer, said, “We are pleased to present updates on our late-stage therapeutic programs for prostate and kidney cancer at ASCO GU 2024, the leading specialised event for GU cancer care worldwide. 

“The ProstACT GLOBAL study of TLX591 (177Lu rosopatamab tetraxetan) will be presented, the first Phase III trial to evaluate TLX591, our lead radio-antibody drug conjugate (rADC) therapy candidate in patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC). 

“Data from the recently completed Phase I ProstACT SELECT study will also be showcased, confirming the clinical validity of Telix’s optimal fractionated dosing and product safety profile.1 Both ProstACT studies are exploring TLX591 administered together with real-world standard of care, differentiating this program from other PSMA studies and reflecting Telix’s continued innovation in prostate cancer care and commitment to patient outcomes. 

“Eric Jonasch MD, will present the STARLITE-1 investigator-initiated trial of Telix’s therapy candidate, TLX250 (177Lu girentuximab), in combination with immunotherapy in clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer. 

“We look forward to seeing you at our booth to discuss Telix’s industry leading theranostic pipeline, our associated medical devices, and opportunities for collaboration.” 

ASCO GU 2024 presentation details are listed below:  


Track: Prostate Cancer- Advanced | Prostate Cancer- Localized 

Type: Trials in Progress Poster Session 

Title: ProstACT SELECT: Safety, tolerability, and dosimetry of TLX591 with best standard of care in patients with PSMA-expressing metastatic castration-resistant prostate cancer 

ClinicalTrials.gov ID: NCT04786847 

Location: Level 1, West Hall | On Demand 

Date and Time: January 25, 2024 | 11:30 AM – 1:00 PM (PT) 

Presenter: Nat Lenzo MD, GenesisCare, AUSTRALIA  

Abstract: TPS253 

Poster Bd: Q14 


Track: Prostate Cancer- Advanced | Prostate Cancer- Localized 

Type: Trials in Progress Poster Session 

Title: ProstACT GLOBAL: A Phase III study of best standard of care with and without TLX591 for patients with PSMA-expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug 

ClinicalTrials.gov ID: NCT04876651 

Location: Level 1, West Hall | On Demand 

Date and Time: January 25, 2024 | 11:30 AM – 1:00 PM (PT) 

Presenter: Brenda Cerqueira, Telix Pharmaceuticals, North Melbourne, AUSTRALIA  

Abstract: TPS256 

Poster Bd: Q17 


Track: Renal Cell Cancer, Adrenal Cancer, Penile Cancer, Testicular Cancer, Urethral Cancer 

Type: Trials in Progress Poster Session 

Title: STARLITE-1: A Phase Ib/II study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC 

ClinicalTrials.gov ID: NCT05663710 

Location: Level 1, West Hall | On Demand 

Date and Time: January 27, 2024 | 7:00 AM – 8:10 AM, 11:30 AM – 1:00 PM (PT)  

Presenter: Eric Jonasch MD, The University of Texas, MD Anderson Cancer Center, Houston, TX 

Abstract: TPS496 

Poster Bd: M17 

Read the full media release here